IvelinRadkov
Vaxxinity (NASDAQ:VAXX) shares traded higher Thursday after the neurology-focused drug developer announced Phase 1 data for its Parkinson’s disease candidate UB-312 following a presentation at a medical event.
UB-312 is designed to target aggregated forms of alpha-synuclein (aSyn), a toxic substance linked to the disease pathology found in the cerebrospinal fluid (CSF) of PD patients.
Citing data from 20 PD patients who were part of Part B of its Phase 1 clinical trial for UB-312, VAXX said that the experimental therapy was generally well tolerated and most adverse events were mild and temporary.
The drug was found to preferentially bind to aggregated aSyn, with almost no binding to normal aSyn.
The company said that the data also indicated a statistically significant correlation between the reductions of aggregated aSyn and changes in a PD clinical measure called MDS-UPDRS II.
In June 2022, Vaxxinity (VAXX) said that Part B of the trial succeeded as UB-312 was well tolerated and led to aSyn antibody responses in patients with early PD.
